Arlo (ARLO) Form 144: 9,171 Shares Proposed Sale; 50,018 Sold Recently
Rhea-AI Filing Summary
Arlo Technologies, Inc. (ARLO) filed a Form 144 notice reporting a proposed sale of 9,171 common shares through Morgan Stanley Smith Barney with an aggregate market value of $155,815.29, noting an approximate sale date of 10/02/2025 on the NYSE. The filing shows those 9,171 shares were acquired as Performance Stock Units from the issuer on 08/08/2025 and the payment classified as compensation on 10/01/2025. The filing also discloses a prior sale in the past three months by Brian Busse of 50,018 common shares on 08/12/2025 for $870,128.13. The notice includes the standard Form 144 representation that the seller does not possess undisclosed material adverse information.
Positive
- Form 144 filed as LIVE, indicating regulatory disclosure compliance
- Broker identified for proposed sale: Morgan Stanley Smith Barney (provides execution transparency)
Negative
- Insider sale disclosed: 50,018 shares sold on 08/12/2025 for $870,128.13
- Proposed sale: 9,171 shares (aggregate value $155,815.29) to be sold on 10/02/2025
Insights
TL;DR: This Form 144 discloses a planned sale of 9,171 ARLO shares and a recent 50,018-share insider sale.
The filing documents a proposed sale of 9,171 shares valued at $155,815.29 to be executed on 10/02/2025 through Morgan Stanley and shows those shares were granted as Performance Stock Units acquired on 08/08/2025. It also records a separate insider sale by Brian Busse of 50,018 shares on 08/12/2025 for $870,128.13.
This is a routine Rule 144 disclosure that notifies the market of insider liquidity events; the numbers and dates provided are the primary facts investors can verify.
TL;DR: The filing shows compensation-related share acquisition followed by planned sale, plus a recent separate insider sale.
The 9,171 shares to be sold were recorded as compensation from the issuer (Performance Stock Units) with acquisition dated 08/08/2025 and payment dated 10/01/2025, indicating the sale relates to recently vested/issued equity. The filing also includes the mandatory seller representation about lack of undisclosed material adverse information.